NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Amgen back to previous page show list

Amgen

»
address: Amgen Limited
240 Cambridge Science Park
Milton Rd
Cambridge CB4 0WD
England
contact: +44 12 2342 0305 (tel)
+44 12 2342 3049 (fax)
www.amgen.co.uk
key person: Ahmed, Nahed
VP, Project Management Research and Development
Beier, David
SVP, Global Government Affairs
Bonanni, Fabrizio
SVP, Manufacturing
Brooks, Craig
VP, Global Marketing
Da

trunover in millions USD: 12400
R & D turnover in millions USD: 2300
NET profit: 0
year of financial results: 2005
employees: 19400

active in China: YES
partner in China: AMGEN GREATER CHINA LTD.

BUSINESS: Pharmaceutical

SFDA approved: NO

Approvals:
GLP: NO
GMP: NO
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: NO
Active Pharmaceutical: NO
R&D: NO
Ingredients: NO
Western Generics: NO
TCM: NO

R & D:
Discovery: NO
Work Up (pilot to production): NO
Analysis: NO
Quality Control: NO
Stability: NO
Batch Release: NO

Clinical trials:
Run/Manage: NO
Data management: NO
Support Labs: NO

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: NO
 
Originally founded in 1980 as AMGen (Applied Molecular Genetics), Amgen pioneered the development of novel and innovative products based on advances in recombinant DNA and molecular biology. More than a decade ago, Amgen introduced two of the first biologically derived human therapeutics, EPOGEN® (Epoetin alfa) and NEUPOGEN® (Filgrastim), which became the biotechnology industry's first blockbusters. These products have improved the lives of hundreds of thousands of patients suffering from conditions related to chronic kidney disease and cancer.
 
Today, Amgen is a Fortune 500 company whose business has expanded to serve patients around the world in supportive cancer care as well as the treatment of anemia, rheumatoid arthritis and other autoimmune diseases such as psoriatic arthritis and ankylosing spondylitis. Amgen continues to sustain a culture rooted in biotechnology entrepreneurialism and innovation. As a science-based and patient-focused organization, we will follow the science wherever it may lead, to best treat serious illness.
 
About Amgen
 
Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine and dramatically improve the quality of people's lives.
 
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.